Methotrexate vs other DMARDs
Function (leflunomide) · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 31 participantsVery low
Findings
What do systematic reviews say?
4,752 questions · 6,648 findings · 688 reviews
No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Rapid susceptibility methods vs standard methods versus placebo
All‐cause mortality · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality compared with standard methods versus placebo (low certainty).
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyRR 1.1 [0.82, 1.46]6 studies · 1638 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Mortality (subgroup genotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup genotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyRR 1.02 [0.69, 1.49]4 studies · 1074 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Mortality (subgroup phenotypic) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (subgroup phenotypic) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyRR 1.37 [0.8, 2.35]2 studies · 564 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Mortality (with stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (with stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyRR 1.17 [0.81, 1.7]4 studies · 1404 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Mortality (without stewardship) · people with bloodstream infections
Rapid susceptibility methods showed no clear difference in mortality (without stewardship) compared with standard methods versus placebo (low certainty).
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyRR 0.89 [0.35, 2.27]2 studies · 234 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Time to hospital discharge · people with bloodstream infections
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 1165 participantsLow
Rapid susceptibility methods vs standard methods versus placebo
Time‐to‐appropriate antibiotic · people with bloodstream infections
1 finding from 1 review
- Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection 2021 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 1493 participantsLow
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin
Cognitive function · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
- Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin
Incidence of MCI · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
- Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin
Incidence of dementia · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
- Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin
Adverse events (Hypoglycaemia) · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
- Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin
All‐cause mortality · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
- Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Dexamethasone vs control
Postoperative wound or systemic infection · participants undergoing surgery
Dexamethasone showed no clear difference in postoperative wound or systemic infection compared with control (moderate certainty).
1 finding from 1 review
- OR 1.01 [0.8, 1.27]26 studies · 4603 participantsModerate
Dexamethasone vs control
Delayed wound healing · participants undergoing surgery
Dexamethasone showed no clear difference in delayed wound healing compared with control (low certainty).
1 finding from 1 review
- OR 0.99 [0.28, 3.43]8 studies · 642 participantsLow
Dexamethasone vs control
Glycaemic response ‐ change from baseline to 2 to 12 hours postoperatively in patients without diabetes · participants undergoing surgery
1 finding from 1 review
- no estimate extracted10 studies · 595 participantsLow
Dexamethasone vs control
Glycaemic response ‐ change from baseline to 10 to 24 hours after surgery in patients with diabetes · participants undergoing surgery
1 finding from 1 review
- no estimate extracted2 studies · 74 participantsVery low
Methylxanthine vs placebo or control
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
- Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes onlyRR 0.87 [0.78, 0.97]1 study · 1869 participantsModerate
Methylxanthine vs placebo or control
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
- Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes onlyRR 1 [0.8, 1.24]1 study · 423 participantsModerate
Methylxanthine vs placebo or control
Death at hospital discharge · preterm infants at risk for apnea
It is very uncertain whether methylxanthine changes death at hospital discharge compared with placebo or control (very low certainty).
1 finding from 1 review
- Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes onlyRR 2.19 [0.85, 5.68]3 studies · 129 participantsVery low